Neoasphenamine Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions

Neoasphenamine Veterinary Grade API is a vacuum-dried complex organoarsenical supplied under release model NEOASP-VET-API-2407 for downstream formulation into tablets, injections, capsules, powders, granules, premixes, and solutions. The bulk powder appears as a pale yellow to light brown amorphous solid. It is manufactured as a veterinary pharmaceutical intermediate and is not a finished dose form. Compendial alignment relies on general pharmacopoeial methods for organoarsenical purity, elemental impurities, residual solvents, and microbial quality because a product-specific harmonized monograph is not currently published. Published data for this specific configuration is limited; release limits should therefore be justified from registration batches and stability studies rather than assumed from human arsenical monographs.

The main differentiation in this grade is the reduction of free aromatic amine content and the control of inorganic arsenic below the threshold applicable to parenteral and oral veterinary formulations. Typical batch documentation includes assay by high-performance liquid chromatography against a qualified reference standard, total arsenic by inductively coupled plasma mass spectrometry, speciation for trivalent and pentavalent inorganic arsenic, water content, particle-size distribution, and bacterial endotoxin for parenteral grades. The material is intended for use under marketing authorization or compounding authorization in the destination jurisdiction.

Assay is performed by reversed-phase high-performance liquid chromatography with ultraviolet detection using a C18 column of 150 mm length and 4.6 mm internal diameter, with a mobile-phase buffer at pH 8.0 and an acetonitrile gradient. Quantification against a qualified reference standard is used, and peak homogeneity is assessed by photodiode array. Mass balance is confirmed by total arsenic determination using inductively coupled plasma mass spectrometry according to USP <233>; speciation for inorganic arsenite and arsenate is included in the impurity profile. Residual solvent control is applied according to USP <467> or Ph. Eur. 2.4.24.

What Limits Oxidation Stability in Aqueous Neoasphenamine Solutions?

Oxidative discoloration and precipitation in aqueous vehicle systems are controlled primarily by headspace oxygen exclusion, low-temperature handling, and pH buffering. In production-scale compounding, the API is dissolved in water for injection that has been sparged with pharmaceutical-grade nitrogen until dissolved oxygen is below 2 mg/L. Vessels are blanketed with nitrogen to maintain residual headspace oxygen below 5% v/v. Solution temperature is held at 5–15°C during mixing and filling because the degradation rate increases rapidly above ambient temperature; published data for this specific configuration is limited, but pilot-batch observations show visible darkening when the temperature exceeds 25°C for periods longer than 90 min. The pH is maintained in the range 7.4–8.0 using a phosphate or borate buffer; below pH 6.5 acid-catalyzed cleavage of the arsenobenzene linkage becomes more evident.

Transition-metal ions, particularly iron(III) and copper(II), accelerate oxidation at trace concentrations. Compounding equipment constructed of 316L stainless steel or glass is preferred. Rubber closures used for injection vials require halogenated stoppers with a low extractable profile; butyl closures without fluoropolymer coating may release metal ions and should be evaluated under Ph. Eur. 3.2.9. The preparation of solutions should be performed under sodium vapour or amber light protection because ultraviolet exposure increases free-radical oxidation. Avoid combination with sulfhydryl-containing excipients, ascorbic acid, and sodium metabisulfite because these reducing agents promote precipitation of arsenic intermediates.

Specification Release Parameters Across Solid and Parenteral Application Routes

The specification matrix for Neoasphenamine Veterinary Grade API is route-dependent. Solid oral premix and granulation grades tolerate wider residual water and particle-size limits than parenteral grades. Parenteral-grade material is tested for bacterial endotoxin and subvisible particulate matter when the finished product is a solution for injection. The table below summarizes general release criteria applied to the bulk API; final registration limits must be confirmed by the finished-product marketing authorization holder.

Residual solvent control is applied according to USP <467> or Ph. Eur. 2.4.24. Methanol, acetone, and isopropyl alcohol are the principal solvents screened in the process validation protocol. No Class 1 solvent should be present above the concentration limit of 5 ppm for benzene and 5 ppm for carbon tetrachloride when calculated by the standard option. Storage in sealed amber glass containers under nitrogen at 2–8°C is required for re-test periods exceeding 12 months.

Process experience from pilot and production-scale blending lines indicates that the powder exhibits cohesive flow behaviour at bulk densities below 0.40 g/mL; die fill variation increases when the material is subjected to storage at relative humidity above 60% without desiccant. Pre-drying at 25–30°C under vacuum for 4–6 h restores flow for direct encapsulation. Equipment surfaces should be earthed because the dry powder can accumulate static charge during transfer through flexible hoses. Dispensing in a low-humidity glovebox or laminar flow booth is recommended, with ambient exposure limited to less than 30 min per dispensing event.

When Neoasphenamine Is Formulated into Medicated Feed Premixes and Granules

For premix and granulation applications, the API is first diluted with a carrier such as lactose monohydrate, calcium carbonate, or ground rice hulls. Low-shear tumble blending at 10–25 rpm for 10–20 min is preferred; high-shear granulation exposes the API to localized temperature rise above 40°C, which can accelerate oxidative degradation. Addition of 0.05–0.20% w/w colloidal silicon dioxide reduces segregation and improves flow without a significant effect on dissolution. The inclusion of reducing sugars should be avoided because they promote reduction and precipitation of arsenic intermediates. If molasses or dextrose carriers are required by the feed formulation, a compatibility study under 25°C/60% RH for 14 days should be conducted before scale-up.

Granule particle-size distribution is controlled by sieve analysis with a target of 90% by weight between 180 µm and 1000 µm for free-flowing premix. Overmixing beyond 20 min can generate fines that segregate during pneumatic conveying. Batch-to-batch variation in bulk density was observed on a 500 kg ribbon-type mixer when carrier moisture varied by more than 1.5% w/w. Equipment contact surfaces should be non-reactive; carbon steel is not recommended because surface iron can accelerate oxidative discoloration and increase the inorganic arsenic fraction during extended storage.

For tablet and capsule manufacture, direct compression or dry granulation is preferred over wet granulation because aqueous granulation solvents increase hydrolysis and require subsequent drying that can accelerate oxidation. Roller compaction at specific force of 8–12 kN/cm with 0.5–1.0 mm screen milling has produced granules suitable for capsule filling. Magnesium stearate at 0.5% w/w is typically compatible, but talc from unvalidated sources should be avoided because trace metal contamination can affect stability. Tablet hardness should be managed to avoid excessive compaction; target friability below 1.0% under USP <1216> is generally sufficient for downstream coating.

Differences from Arsphenamine Dihydrochloride and Roxarsone-Type Feed Additives

Neoasphenamine differs from arsphenamine dihydrochloride in aqueous solubility, pH after dissolution, and parenteral formulation suitability. Arsphenamine requires dissolution in alkaline solution before injection and is not supplied as a ready-to-compound neutral salt. Neoasphenamine carries a N-methylene sulfinate/sulfonate substitution that increases water solubility and lowers free aromatic amine reactivity; however, oxidation sensitivity remains a critical control point. Roxarsone and related phenylarsonic acid feed additives are used in different livestock production contexts and have different regulatory status; they are not interchangeable with Neoasphenamine in injectable or tablet formulations.

For solution dosage forms intended for parenteral administration, Neoasphenamine is dissolved in water for injection under nitrogen and filtered through a 0.22 µm membrane. Terminal sterilisation is not generally applied because of thermal sensitivity; aseptic processing is used. Tonicity adjustment is performed with sodium chloride at 9.0 g/L, and the pH is adjusted with dilute sodium hydroxide or hydrochloric acid. The finished solution should be filled into amber Type I glass vials under nitrogen and stored at 2–8°C. Long-term storage beyond 24 h at room temperature is not recommended because of colour change and precipitation. For oral solutions, similar principles apply, but short-term stability may be improved by using a non-reducing vehicle system and avoiding metal-ion contamination.

The API should not be exposed to open air for extended periods after the primary container is opened. Once opened, the container should be re-sealed under nitrogen and returned to refrigerated storage. Any material that has become dark brown, sticky, or shows visible particulate formation after reconstitution should be rejected. These operational boundaries are essential because the organoarsenical backbone is prone to oxygen- and light-mediated transformation, and the resulting impurity profile can shift outside the validated specification range for parenteral or oral veterinary use.